Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05372354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 160 to 260 Primary endpoints: 3 to 7 · Secondary endpoints: 9 to 12 · Site details revised at 3 of 17 sites · 1 morev17 Show 4 more changesShow less
    • Primary endpoints: 3 to 7
    • Secondary endpoints: 9 to 12
    • Site details revised at 3 of 17 sites
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 220 to 160 Eligibility criteria expanded, about 59 words · Site details revised at 4 of 17 sites · Study arms: 7 to 6v16 Show 3 more changesShow less
    • Eligibility criteria expanded, about 59 words
    • Site details revised at 4 of 17 sites
    • Study arms: 7 to 6

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (17)v15 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (17)v14 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (17)v13 See this version in full on ClinicalTrials.gov ↗
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 16 to 17v12
  2. Study sites: 15 to 16v11
  3. Study sites: 14 to 15v10
  4. Study sites: 13 to 14v9
  5. Study sites: 12 to 13v8
  6. Study sites: 11 to 12v7
  7. Study sites: 10 to 11 Start date changed from estimate of Oct 31, 2022 to Oct 18, 2022v6 Show 1 more changeShow less
    • Start date changed from estimate of Oct 31, 2022 to Oct 18, 2022
  8. Study sites: 9 to 10v5
  9. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Apr 4, 2025 to Oct 12, 2026 · Start date: Aug 31, 2022 to Oct 31, 2022 · Study sites: 6 to 9v4 Show 3 more changesShow less
    • Primary and study completion dates: Apr 4, 2025 to Oct 12, 2026
    • Start date: Aug 31, 2022 to Oct 31, 2022
    • Study sites: 6 to 9
  10. Study sites: 5 to 6v3
  11. Start date: Jun 30, 2022 to Aug 31, 2022 Study sites: 1 to 5v2 Show 1 more changeShow less
    • Study sites: 1 to 5
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Trial Details
NCT Number NCT05372354
Lead Sponsor Bristol-Myers Squibb
Conditions Multiple Myeloma
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov